Search the Newsreel

Sonoma Pharmaceuticals, Inc. Q1 2027: Revenue $6.41M, EPS $(0.09) — 10-Q Summary

Sonoma Pharmaceuticals, Inc. reported Q1 2027 results with revenue increasing to $6.41 million, a 60% year-over-year rise, and a narrowed net loss of $0.33 million, improving from the prior year. This growth was driven by a 141% increase in U.S. sales, led by OTC …

Sonoma U.S. Revenue Climbs 141%; First-Ever Positive Adjusted EBITDA

Sonoma Pharmaceuticals (NASDAQ: SNOA) reported a significant 60% year-over-year increase in fiscal Q1 2027 revenue to $6.4 million, driven by a 141% surge in U.S. sales and global growth. The company achieved its first-ever positive adjusted EBITDA of $0.05 million and expanded its gross …

SNOA|Sonoma Pharmaceuticals Inc|Price:1.100|Chg%:-0.040

Sonoma Pharmaceuticals Inc. (SNOA) shows strong fundamentals with high growth potential, averaging 53.35% revenue growth over three years. Despite recent stock market underperformance, its valuation is considered fairly valued within the Pharmaceuticals industry. The company, which develops and produces stabilized hypochlorous acid (HOCl) products …

Sonoma Pharmaceuticals Inc (SNOA) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Sonoma Pharmaceuticals Inc (SNOA), detailing its current risk score of 3.07 within the Pharmaceuticals industry. Key metrics such as beta value, maximum drawdown, volatility, and various return and liquidity indicators are presented. The assessment highlights the stock's …

Sonoma Pharmaceuticals (Nasdaq: SNOA) 2026 pay, board and auditor votes

Sonoma Pharmaceuticals (SNOA) has issued its definitive proxy statement for the 2026 Annual Meeting, scheduled for September 16, 2026. Shareholders will vote on the re-election of Class III director Jerry McLaughlin, an advisory approval of executive compensation for fiscal year 2026, and the ratification …

Sonoma Pharmaceuticals Inc (SNOA) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides an overview of the shareholder structure of Sonoma Pharmaceuticals Inc (SNOA), detailing major shareholders and institutional holdings. It lists the proportion of shares held by entities like DRW Securities, Vanguard Capital Management, and Geode Capital Management, as well as various shareholder …

Sonoma Pharmaceuticals Inc (SNOA) Institutional Confidence

This article provides an overview of Sonoma Pharmaceuticals Inc. (SNOA) institutional confidence score and shareholder activity as of July 27, 2026. DRW Securities, LLC notably increased its shares held by 257.22%, while other institutions like Geode Capital Management and Global Retirement Partners also reported …

Sonoma Pharmaceuticals Inc (SNOA) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Sonoma Pharmaceuticals Inc (SNOA)'s dividend history and stock split events. It states that the company has distributed $0.00 in dividends over the past five years and details multiple 20-to-1 merger-related stock splits scheduled for August 28, 2024. The …

SNOA|Sonoma Pharmaceuticals Inc|Price:1.140|Chg%:-0.020

This article provides a detailed financial overview of Sonoma Pharmaceuticals Inc. (SNOA), including its stock price, market cap, and key financial metrics from its latest FY2026 earnings report. It highlights revenue, EPS, net profit, various margins, and balance sheet and cash flow statements, offering …

TradingKey

This article provides a detailed quarterly and annual cash flow statement for Sonoma Pharmaceuticals Inc (SNOA), covering operating, investing, and financing activities over several fiscal years. It also includes frequently asked questions about different types of cash flow, their significance, and how Sonoma Pharmaceuticals …

19,898 Common Stock of Sonoma Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 24-JUL-2026.

19,898 shares of common stock of Sonoma Pharmaceuticals, Inc. are currently under a 91-day lock-up agreement, which began on April 24, 2026, and is set to end on July 24, 2026. This agreement restricts the company's officers and directors from selling or disposing of …

Sonoma Pharmaceuticals Q2 2026 Earnings: EPS Miss Sends Shares Lower - EPS Growth Rate

SNOA Q1 2026 Earnings: EPS Misses Estimates by 1.2%, No Revenue Reported, Stock Edges Up 0.87%

SNOA Drops As Sonoma Pharmaceuticals Launches Dilutive Offering

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Could Be Riskier Than It Looks

Sonoma Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

Sonoma Pharmaceuticals (SNOA) Stock Price, News & Analysis